LEM 5 mg + LEM 10 mg
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Insomnia
Conditions
Insomnia
Trial Timeline
Jul 15, 2019 โ Jun 26, 2020
NCT ID
NCT04009577About LEM 5 mg + LEM 10 mg
LEM 5 mg + LEM 10 mg is a phase 3 stage product being developed by Eisai for Insomnia. The current trial status is completed. This product is registered under clinical trial identifier NCT04009577. Target conditions include Insomnia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04009577 | Phase 3 | Completed |
Competing Products
20 competing products in Insomnia